Comparing 2 hypotheses side-by-side
## Mechanistic Overview Tau Cross-Seeding and Interaction starts from the claim that modulating MAPT within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Tau Cross-Seeding and Interaction starts from the claim that modulating MAPT within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Tau Cross-Seeding and Interact
## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Tau Cross-Seeding and Interact | Glymphatic-Mediated Tau Cleara |
|---|---|---|
| Mechanistic | 0.730 | 0.800 |
| Evidence | 0.680 | 0.720 |
| Novelty | 0.720 | 0.850 |
| Feasibility | 0.650 | 0.680 |
| Impact | 0.700 | 0.780 |
| Druggability | 0.550 | 0.450 |
| Safety | 0.450 | 0.650 |
| Competition | 0.500 | 0.820 |
| Data | 0.600 | 0.700 |
| Reproducible | 0.520 | 0.630 |
| KG Connect | 0.500 | 0.838 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.73
# Mechanistic Hypotheses: TDP-43 Contribution to Cognitive Impairment Severity in AD ## Hypothesis 1: Synaptic RNA Metabolism Dysregulation **Title:** TDP-43-mediated disruption of synaptic mRNA tra...
# Critical Evaluation of TDP-43 Cognitive Impairment Mechanisms in AD ## Hypothesis 1: Synaptic RNA Metabolism Dysregulation **Weak Links:** - **Assumes nuclear loss-of-function dominance**: In AD, ...
# Feasibility Assessment: TDP-43 Mechanisms in AD Cognitive Impairment ## Pre-Assessment Filter | Hypothesis | Theorist Confidence | Skeptic Revised | Survives? | Rationale | |------------|---------...
{"ranked_hypotheses":[{"title":"Glial Neuroinflammatory Amplification by TDP-43 Pathology","description":"TDP-43 pathology in astrocytes and microglia drives non-cell-autonomous neuroinflammation thro...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["MAPT gene
expression"]
B["Tau protein
production"]
C["Hyperphosphorylated
tau accumulation"]
D["Locus coeruleus
neurons"]
E["Microtubule
destabilization"]
F["Axonal transport
impairment"]
G["Norepinephrine
release reduction"]
H["Hippocampal
noradrenergic
denervation"]
I["Synaptic plasticity
dysfunction"]
J["Neuroinflammation
activation"]
K["Cellular stress
response failure"]
L["Hippocampal tau
pathology spread"]
M["Memory and
cognitive decline"]
N["Noradrenergic
replacement therapy"]
O["Tau aggregation
inhibitors"]
A -->|"transcription"| B
B -->|"pathological
modification"| C
C -->|"selective
vulnerability"| D
D -->|"tau toxicity"| E
E -->|"transport
disruption"| F
F -->|"neurotransmitter
depletion"| G
G -->|"circuit
disconnection"| H
H -->|"loss of
modulation"| I
H -->|"reduced
anti-inflammatory"| J
H -->|"impaired
neuroprotection"| K
I -->|"functional
decline"| M
J -->|"tissue
damage"| L
K -->|"vulnerability
increase"| L
L -->|"progressive
pathology"| M
N -->|"circuit
restoration"| H
O -->|"tau
reduction"| C
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,D,G molecular
class E,F,I,K normal
class C,H,J,L pathology
class M outcome
class N,O therapeutic